PBMs: Friends or Foes?
Healthcare Unfiltered
00:00
The Role of Biosimilars in Rheumatology
PBM's get a really bad reputation is, you know, and health plans too. But if they set it up so that patients are paying based on the list price, which happens quite a lot now, then we should be critical of them using these rebates as the way of negotiating. It basically then overcharges the patients for their drugs relative to what their contribution is supposed to be. So my general view is like, I don't have a problem with PBM's if and rebates, if we can protect the patient from having Their price tied to that list price, I think patients should pay co-pays period.
Transcript
Play full episode
